Columbia Wanger Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Columbia Wanger Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-641,932	Closed	-$12.2M	–	205
2016 Q2	$12.2M	Sell	641,932 -477,961	-43%	-$8.85M	0.14%	172
2016 Q1	$21.9M	Sell	1,119,893 -44,797	-4%	-$783K	0.24%	133
2015 Q4	$44.9M	Sell	1,164,690 -968,994	-45%	-$31.4M	0.45%	89
2015 Q3	$68.5M	Sell	2,133,684 -1,398,993	-40%	-$47.5M	0.55%	75
2015 Q2	$107M	Buy	3,532,677 +260,277	+8%	+$5.32M	0.69%	43
2015 Q1	$43.5M	Hold	3,272,400	–	–	0.24%	150
2014 Q4	$47.4M	Buy	3,272,400 +35,400	+1%	+$599K	0.23%	145
2014 Q3	$68.3M	Buy	3,237,000 +604,000	+23%	+$13.6M	0.31%	111
2014 Q2	$78.4M	Hold	2,633,000	–	–	0.31%	113
2014 Q1	$63.3M	Sell	2,633,000 -2,000	-0.1%	-$51K	0.25%	138
2013 Q4	$53.7M	Buy	2,635,000 +1,204,000	+84%	+$35.8M	0.21%	161
2013 Q3	$67.6M	Sell	1,431,000 -356,000	-20%	-$13.7M	0.27%	128
2013 Q2	$68M	Buy	+1,787,000	New	+$63.9M	0.3%	117

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Columbia Wanger Asset Management's SRPT Position: Q3 2016 in Review

Columbia Wanger Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 641,932 shares — an estimated $12.2M sold.

Columbia Wanger Asset Management first reported a position in SRPT in Q2 2013 and held it in 13 quarters. The position peaked at $107M in Q2 2015. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

Columbia Wanger Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
Columbia Wanger Asset Management sold 641,932 Sarepta Therapeutics shares in Q3 2016, an estimated $12.2M.
Columbia Wanger Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 13 quarters.
Columbia Wanger Asset Management's Sarepta Therapeutics position peaked at $107M in Q2 2015.
186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Columbia Wanger Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.